Τρίτη, 10 Νοεμβρίου 2015

CHEMOTHERAPY CHOISE FOR PATIENTS WITH KRAS MUTATED NSCLC

 2015 Nov;90(2):249-54. doi: 10.1016/j.lungcan.2015.09.012. Epub 2015 Sep 15.

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.

Abstract

OBJECTIVES: 

As suggested by in-vitro data, we hypothesize that subtypes of KRAS mutated non-small cell lung cancer (NSCLC) respond differently to chemotherapy regimens.

METHODS: 

Patients with advanced NSCLC and known KRAS mutation, treated with first-line platinum-based chemotherapy, were retrieved from hospital databases.

PRIMARY OBJECTIVE: 

to investigate overall response rate (ORR), progression free survival (PFS) and overall survival (OS) between different types of platinum-based chemotherapy per type of KRAS mutation.

RESULTS: 

464 patients from 17 hospitals, treated between 2000 and 2013, were included. The majority of patients had stage IV disease (93%), had a history of smoking (98%) and known with an adenocarcinoma (91%). Most common types of KRAS mutation were G12C (46%), G12V (20%) and G12D (10%). Platinum was combined with pemetrexed (n=334), taxanes (n=68) or gemcitabine (n=62). Patients treated with taxanes had a significant improved ORR (50%) compared to pemetrexed (21%) or gemcitabine (25%; p<0 .01="" abstracttext="" addition="" all="" and="" bevacizumab="" but="" comparable="" compared="" for="" g12c="" g12d="" g12v="" groups.="" had="" highest="" improved="" in="" mutation="" n="38)" not="" observed="" or="" orr="" os.="" os="" p="" patients="" pemetrexed="" pfs="" significantly="" taxanes="" the="" to="" treated="" treatment="" was="" with="">

CONCLUSION: 

KRAS mutated NSCLC patients treated with taxane-based chemotherapy had best ORR. Response to chemotherapy regimens was different in types of KRAS mutation. Especially patients with G12V had better response to taxane treatment.

Δεν υπάρχουν σχόλια: